Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro.

Gould WR, McClanahan TB, Welch KM, Baxi SM, Saiya-Cork K, Chi L, Johnson TR, Leadley RJ.

J Thromb Haemost. 2006 Apr;4(4):834-41.

2.

Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.

Willardsen JA, Dudley DA, Cody WL, Chi L, McClanahan TB, Mertz TE, Potoczak RE, Narasimhan LS, Holland DR, Rapundalo ST, Edmunds JJ.

J Med Chem. 2004 Jul 29;47(16):4089-99.

PMID:
15267248
3.

The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.

McClanahan TB, Hicks GW, Morrison AL, Peng YW, Janiczek-Dolphin N, Mertz TE, Sullivan ME, Morser J, Juneau PL, Leadley R.

Eur J Pharmacol. 2001 Dec 7;432(2-3):187-94.

PMID:
11740955
4.

Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.

Ignasiak DP, McClanahan TB, Bousley RE, Juneau PL, Gallagher KP.

J Thromb Thrombolysis. 1998 Nov;6(3):199-206.

PMID:
10751802
5.

The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis.

McClanahan TB, Hicks GW, Ignasiak DP, Bousley R, Mertz TE, Juneau P, Janiczek-Dolphin N, Kim IC, Gallagher KP.

J Thromb Thrombolysis. 2000 Dec;10(3):277-84.

PMID:
11122549
6.

Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.

Dudley DA, Bunker AM, Chi L, Cody WL, Holland DR, Ignasiak DP, Janiczek-Dolphin N, McClanahan TB, Mertz TE, Narasimhan LS, Rapundalo ST, Trautschold JA, Van Huis CA, Edmunds JJ.

J Med Chem. 2000 Nov 2;43(22):4063-70.

PMID:
11063603
7.

Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.

McClanahan TB, Ignasiak DP, Juneau P, Finkle C, Winocour PD, Gallagher KP.

J Thromb Thrombolysis. 1999 Jun;7(3):301-6.

PMID:
10375391
8.

Effects of ischemia, preconditioning, and adenosine deaminase inhibition on interstitial adenosine levels and infarct size.

Martin BJ, McClanahan TB, Van Wylen DG, Gallagher KP.

Basic Res Cardiol. 1997 Aug;92(4):240-51. Erratum in: Basic Res Cardiol 1997 Dec;92(6):435.

PMID:
9342431
9.

Effects of endothelin ETA receptor antagonism with PD 156707 on hemodynamics and renal vascular resistance in rabbits.

Ignasiak DP, McClanahan TB, Saganek LJ, Potoczak RE, Hallak H, Gallagher KP.

Eur J Pharmacol. 1997 Mar 5;321(3):295-300.

PMID:
9085040
10.

Effects of endothelin-receptor antagonism with PD156707 on myocardial stunning in swine.

McClanahan TB, Mertz TE, Ignasiak DP, Juneau PL, Gallagher KP.

J Cardiovasc Pharmacol. 1996 Nov;28(5):679-86.

PMID:
8945682
11.

Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs.

Mertz TE, McClanahan TB, Flynn MA, Juneau P, Reynolds EE, Hallak H, Bradford L, Gallagher KP.

J Pharmacol Exp Ther. 1996 Jul;278(1):42-9.

PMID:
8764334
12.

Effect of adenosine deaminase inhibition with pentostatin on myocardial stunning in dogs.

McClanahan TB, Ignasiak DP, Martin BJ, Mertz TE, Gallagher KP.

Basic Res Cardiol. 1995 Mar-Apr;90(2):176-83.

PMID:
7646420
13.

Tumor necrosis factor and interleukin-6 are not elevated in venous blood from ischemic canine myocardium.

Field G, Conn CA, McClanahan TB, Nao BS, Kluger MJ, Gallagher KP.

Proc Soc Exp Biol Med. 1994 Sep;206(4):384-91.

PMID:
8073047
14.

Does adenosine deaminase inhibition protect ischemic myocardium?

Gallagher KP, McClanahan TB, Martin BJ, Saganek LJ, Ignasiak DP, Mertz TE, Van Wylen DG, Vinten-Johansen J.

Adv Exp Med Biol. 1994;370:291-4. Review. No abstract available.

PMID:
7660911
15.

The relationship between myocardial blood flow and glucose uptake in ischemic canine myocardium determined with fluorine-18-deoxyglucose.

Kalff V, Schwaiger M, Nguyen N, McClanahan TB, Gallagher KP.

J Nucl Med. 1992 Jul;33(7):1346-53.

16.

Effects of ischemia on epicardial segment shortening.

Stirling MC, Choy M, McClanahan TB, Schott RJ, Gallagher KP.

J Surg Res. 1991 Jan;50(1):30-9.

17.

Hemodynamic effects of intraatrial administration of deferoxamine or deferoxamine-pentafraction conjugate to conscious dogs.

Forder JR, McClanahan TB, Gallagher KP, Hedlund BE, Hallaway PE, Shlafer M.

J Cardiovasc Pharmacol. 1990 Nov;16(5):742-9.

PMID:
1703595
18.

Distribution of cardioplegic solution infused antegradely and retrogradely in normal canine hearts.

Stirling MC, McClanahan TB, Schott RJ, Lynch MJ, Bolling SF, Kirsh MM, Gallagher KP.

J Thorac Cardiovasc Surg. 1989 Dec;98(6):1066-76.

PMID:
2586122
19.

F(ab')2 fragments of anti-Mo1 (904) monoclonal antibodies do not prevent myocardial stunning.

Schott RJ, Nao BS, McClanahan TB, Simpson PJ, Stirling MC, Todd RF 3rd, Gallagher KP.

Circ Res. 1989 Oct;65(4):1112-24.

PMID:
2551527
20.

Increase in experimental infarct size with digoxin in a canine model of myocardial ischemia-reperfusion injury.

Lynch JJ, Simpson PJ, Gallagher KP, McClanahan TB, Lee KA, Lucchesi BR.

Am Heart J. 1988 Jun;115(6):1171-82.

21.

Changes in contractility fail to alter the size of the functional border zone in anesthetized dogs.

Drake DH, McClanahan TB, Ning XH, Gerren RA, Dunham WR, Gallagher KP.

Circ Res. 1987 Aug;61(2):166-80.

PMID:
3621483

Supplemental Content

Loading ...
Support Center